Related Experiment Video

Updated: Dec 4, 2025

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.5K

miR-150 regulates glucose utilization through targeting GLUT4 in insulin-resistant cardiomyocytes

Jin Ju1, Dan Xiao1,2, Nannan Shen1,3

  • 1Department of Pharmacology, Harbin Medical University (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.

Acta Biochimica Et Biophysica Sinica
|October 21, 2020
PubMed

Insights

MicroRNAs (miRNAs) regulate glucose metabolism in heart cells. This study shows that elevated miR-150 in insulin resistance impairs glucose uptake by reducing glucose transporter 4 (GLUT4), suggesting miR-150 as a therapeutic target for type 2 diabetes mellitus.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Regulation
  • Molecular Genetics

Background:

  • MicroRNAs (miRNAs) are crucial regulators of cardiac function and metabolism.
  • The role of miRNAs in cardiomyocyte insulin resistance (IR) is not fully understood.
  • Investigating specific miRNAs like miR-150 is key to understanding metabolic dysregulation in the heart.

Purpose of the Study:

  • To investigate the role of miR-150 in cardiomyocyte insulin resistance.
  • To determine the impact of miR-150 on glucose transporter 4 (GLUT4) expression and translocation.
  • To explore miR-150 as a potential therapeutic target for type 2 diabetes mellitus (T2DM).

Main Methods:

  • Western blot, real-time PCR, and immunofluorescence assays to assess GLUT4 levels.
  • 2-deoxyglucose transport and glucose consumption assays to measure glucose utilization.
  • In vitro models of insulin-resistant cardiomyocytes and in vivo T2DM rat models.

Main Results:

  • miR-150 levels were elevated in T2DM rat hearts and insulin-resistant cardiomyocytes.
  • miR-150 downregulation reduced GLUT4 protein and mRNA.
  • Overexpression of miR-150 inhibited glucose uptake, while knockdown increased it.
  • miR-150 inhibition promoted GLUT4 translocation.

Conclusions:

  • miR-150 exacerbates insulin resistance in cardiomyocytes by decreasing GLUT4 expression and translocation.
  • miR-150 is a potential therapeutic target for managing metabolic diseases like T2DM.
  • Understanding miR-150's role provides insights into cardiac metabolic dysfunction.
Keywords:
GLUT4insulin resistancemiR-150type 2 diabetes mellitus

More Related Videos

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

6.3K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

475

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
5.9K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.4K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
493
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
419
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
661